Charles River Labs (CRL) Stock Forecast & Price Target

Compare

564 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CRL Analyst Ratings

Moderate Buy

4 Buy

8 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Charles

River Labs

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CRL Stock 12 Month Forecast

Average Price Target

$171.00

▲(4.45% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Charles River Labs in the last 3 months. The average price target is $171.00 with a high forecast of $190.00 and a low forecast of $151.00. The average price target represents a 4.45% change from the last price of $163.71.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"115":"$115","147":"$147","179":"$179","211":"$211","243":"$243"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":190,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$190.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":171,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$171.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":151,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$151.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[115,147,179,211,243],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,166.91,168.68615384615384,170.4623076923077,172.23846153846154,174.01461538461538,175.79076923076923,177.56692307692308,179.34307692307692,181.11923076923077,182.89538461538461,184.67153846153846,186.4476923076923,188.22384615384615,{"y":190,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,166.91,167.2246153846154,167.53923076923076,167.85384615384615,168.16846153846154,168.4830769230769,168.7976923076923,169.1123076923077,169.4269230769231,169.74153846153845,170.05615384615385,170.37076923076924,170.6853846153846,{"y":171,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,166.91,165.68615384615384,164.4623076923077,163.23846153846154,162.01461538461538,160.79076923076923,159.56692307692308,158.34307692307692,157.11923076923077,155.89538461538461,154.67153846153846,153.4476923076923,152.22384615384615,{"y":151,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":242.84,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":197.75,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":194.08,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":180.96,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":201.25,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.76,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.31,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":145.99,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":116.89,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.04,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$190.00

Average Price Target$171.00

Lowest Price Target$151.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Cira Diagnissa

TR | OpenAI - 4o

$156→$167

Hold

2.01%

Upside

Reiterated

08/23/25

AI Generated ArticleAI Generated Article

Charles Rhyee

TD Cowen

$179

Buy

9.34%

Upside

Reiterated

08/11/25

Charles River Labs: Stability and Long-term Value Creation Potential Amidst Short-term ChallengesWe believe two items drove most of the negative reaction: 1) mgmt. calling out elevated cancelations (highest in 3 Qs) and 2) guiding its 2H B2B to a "similar zipcode" as in its DSA segment. Following a 1Q where some were seeking to assess whether a 1Q spike in DSA demand could be an indicator of a turnaround (ie. potential re-prioritizing of preclinical spend, flow-through of recent healthy biotech funding), 2Q did not support this thesis. Mgmt. noting seeing a stable environment in both large pharma and biotech, and guiding to a stable B2B in 2H, is still a positive in our view, as CRL appears confident that demand should be stable at current levels going forward.

Dan Leonard

UBS

$150→$170

Hold

3.84%

Upside

Reiterated

08/07/25

UBS Keeps Their Hold Rating on Charles River Labs (CRL)

Eric Coldwell

Robert W. Baird

$140→$151

Hold

-7.76%

Downside

Reiterated

08/07/25

Charles River Labs (CRL) Gets a Hold from Robert W. Baird

Tejas Savant

Morgan Stanley

$168→$170

Hold

3.84%

Upside

Reiterated

08/07/25

Morgan Stanley Keeps Their Hold Rating on Charles River Labs (CRL)

Casey Woodring

J.P. Morgan

$160

Hold

-2.27%

Downside

Reiterated

08/07/25

J.P. Morgan Reaffirms Their Hold Rating on Charles River Labs (CRL)

Justin Bowers

Deutsche Bank

$180→$185

Buy

13.00%

Upside

Reiterated

08/07/25

Deutsche Bank Keeps Their Buy Rating on Charles River Labs (CRL)

Elizabeth Anderson CFA

Evercore ISI

$170→$190

Buy

16.06%

Upside

Reiterated

08/07/25

Evercore ISI Sticks to Their Buy Rating for Charles River Labs (CRL)

Luke Sergott

Barclays

$155→$165

Hold

0.79%

Upside

Reiterated

08/07/25

Barclays Keeps Their Hold Rating on Charles River Labs (CRL)

Michael Ryskin

Bank of America Securities

$170→$175

Hold

6.90%

Upside

Reiterated

08/06/25

Charles River price target raised to $175 from $170 at BofACharles River price target raised to $175 from $170 at BofA

Max Smock

William Blair

―

Hold

―

Reiterated

08/06/25

Balanced Outlook: Charles River Labs' Strong Performance Amid Cautionary Signals Justifies Hold Rating

Unknown Analyst

CFRA

Not Ranked

CFRA

$165

Hold

0.79%

Upside

Downgraded

07/14/25

CFRA downgrades Charles River Labs (CRL) to a Hold

Patrick B Donnelly

Citi

―

Buy

―

Upgraded

07/09/25

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (NASDAQ: APLS) and Charles River Labs (NYSE: CRL)

Jamie Clark

Redburn Atlantic

$188→$182

Buy

11.17%

Upside

Upgraded

05/23/25

Charles River upgraded to Buy from Neutral at Redburn AtlanticCharles River upgraded to Buy from Neutral at Redburn Atlantic

David Windley

Jefferies

$169→$100

Hold

-38.92%

Downside

Reiterated

04/21/25

Charles River Labs (CRL) PT Lowered to $100 at JefferiesJefferies analyst David Windley lowered the price target on Charles River Labs (NYSE: CRL) to $100.00 (from $169.00) while maintaining a Hold rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Cira Diagnissa

TR | OpenAI - 4o

$156→$167

Hold

2.01%

Upside

Reiterated

08/23/25

AI Generated ArticleAI Generated Article

Charles Rhyee

TD Cowen

$179

Buy

9.34%

Upside

Reiterated

08/11/25

Dan Leonard

UBS

$150→$170

Hold

3.84%

Upside

Reiterated

08/07/25

UBS Keeps Their Hold Rating on Charles River Labs (CRL)

Eric Coldwell

Robert W. Baird

$140→$151

Hold

-7.76%

Downside

Reiterated

08/07/25

Charles River Labs (CRL) Gets a Hold from Robert W. Baird

Tejas Savant

Morgan Stanley

$168→$170

Hold

3.84%

Upside

Reiterated

08/07/25

Morgan Stanley Keeps Their Hold Rating on Charles River Labs (CRL)

Casey Woodring

J.P. Morgan

$160

Hold

-2.27%

Downside

Reiterated

08/07/25

J.P. Morgan Reaffirms Their Hold Rating on Charles River Labs (CRL)

Justin Bowers

Deutsche Bank

$180→$185

Buy

13.00%

Upside

Reiterated

08/07/25

Deutsche Bank Keeps Their Buy Rating on Charles River Labs (CRL)

Elizabeth Anderson CFA

Evercore ISI

$170→$190

Buy

16.06%

Upside

Reiterated

08/07/25

Evercore ISI Sticks to Their Buy Rating for Charles River Labs (CRL)

Luke Sergott

Barclays

$155→$165

Hold

0.79%

Upside

Reiterated

08/07/25

Barclays Keeps Their Hold Rating on Charles River Labs (CRL)

Michael Ryskin

Bank of America Securities

$170→$175

Hold

6.90%

Upside

Reiterated

08/06/25

Charles River price target raised to $175 from $170 at BofACharles River price target raised to $175 from $170 at BofA

Max Smock

William Blair

―

Hold

―

Reiterated

08/06/25

Balanced Outlook: Charles River Labs' Strong Performance Amid Cautionary Signals Justifies Hold Rating

Unknown Analyst

CFRA

Not Ranked

CFRA

$165

Hold

0.79%

Upside

Downgraded

07/14/25

CFRA downgrades Charles River Labs (CRL) to a Hold

Patrick B Donnelly

Citi

―

Buy

―

Upgraded

07/09/25

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (NASDAQ: APLS) and Charles River Labs (NYSE: CRL)

Jamie Clark

Redburn Atlantic

$188→$182

Buy

11.17%

Upside

Upgraded

05/23/25

Charles River upgraded to Buy from Neutral at Redburn AtlanticCharles River upgraded to Buy from Neutral at Redburn Atlantic

David Windley

Jefferies

$169→$100

Hold

-38.92%

Downside

Reiterated

04/21/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Charles River Labs

1 Month

xxx

Success Rate

7/11 ratings generated profit

Average Return

+2.64%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +2.64% per trade.

3 Months

xxx

Success Rate

8/11 ratings generated profit

Average Return

+5.64%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +5.64% per trade.

1 Year

Patrick B DonnellyCiti

Success Rate

9/12 ratings generated profit

Average Return

+16.61%

upgraded a buy rating 2 months ago

Copying Patrick B Donnelly's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +16.61% per trade.

2 Years

xxx

Success Rate

9/12 ratings generated profit

Average Return

+15.43%

upgraded a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +15.43% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRL Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CRL has received 13 Buy Ratings, 17 Hold Ratings, and 0 Sell Ratings. CRL average Analyst price target in the past 3 months is 171.00.

Each month's total comprises the sum of three months' worth of ratings.

CRL Financial Forecast

CRL Earnings Forecast

Next quarter’s earnings estimate for CRL is $2.34 with a range of $2.30 to $2.45. The previous quarter’s EPS was $3.12. CRL beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.17% of the time in the same period. In the last calendar year CRL has Outperformed its overall industry.

CRL Sales Forecast

Next quarter’s sales forecast for CRL is $980.48M with a range of $954.60M to $1.01B. The previous quarter’s sales results were $1.03B. CRL beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.90% of the time in the same period. In the last calendar year CRL has Outperformed its overall industry.

CRL Stock Forecast FAQ

What is CRL’s average 12-month price target, according to analysts?

Based on analyst ratings, Charles River Laboratories Intl’s 12-month average price target is 171.00.

What is CRL’s upside potential, based on the analysts’ average price target?

Charles River Laboratories Intl has 4.45% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CRL a Buy, Sell or Hold?

Charles River Laboratories Intl has a consensus rating of Moderate Buy which is based on 4 buy ratings, 8 hold ratings and 0 sell ratings.

What is Charles River Laboratories Intl’s price target?

The average price target for Charles River Laboratories Intl is 171.00. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $190.00 ,the lowest forecast is $151.00. The average price target represents 4.45% Increase from the current price of $163.71.

What do analysts say about Charles River Laboratories Intl?

Charles River Laboratories Intl’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of CRL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Charles River Labs (CRL) Stock Forecast & Price Target

CRL Analyst Ratings

CRL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Charles River Labs

CRL Analyst Recommendation Trends

CRL Financial Forecast

CRL Earnings Forecast

CRL Sales Forecast

CRL Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts